Latest Content

Review the news from this year's Clinical Trials in Alzheimer's Disease conference.

A psychiatric reflects on a true gift, envisioning a future of hope, healing, and inclusion and celebrating the power of unity and compassion.

See the variety of commentary, news, and happenings in artificial intelligence (AI) and psychiatry throughout this year.

See the latest developments in narcolepsy research.

Syremis Therapeutics advances innovative drugs ST-905 and ST-901 for schizophrenia and major depressive disorder, aiming to transform mental health treatment.

During the holidays, can we blend tradition with modern media habits without sacrificing the meaning?

Cobenfy gains NMPA approval in China, offering a groundbreaking treatment for schizophrenia with a unique mechanism and improved symptom management.

In this CME article, explore effective strategies for managing sleep disturbances in elite athletes, focusing on pharmacologic and nonpharmacologic interventions.

Reviva Pharmaceuticals announced FDA recommendations from their pre-NDA meeting on brilaroxazine for schizophrenia.

An open letter urges lawmakers to regulate AI chatbots, highlighting their dangers to children's emotional development and mental health.

Let's examine the vital intersection of religion, spirituality, and mental health, revealing their powerful role in enhancing patient care and well-being.

The tragedy sheds light on the complexities of parricide and loss.